EICHORCondition: Multiple Sclerosis · Sponsor: Zuyderland Medisch Centrum
Interested? Contact the study team ↓
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non-traumatic neurological disability in young adults. Magnetic resonance imaging (MRI) is the most important paraclinical investigation used in the diagnosis and monitoring of the disease. In the past years, spinal cord MRI has improved significantly and has become an important part of the diagnostic workup for MS. Presently, follow-up imaging of the spinal cord is only performed when spinal cord related symptoms occur. However, there is increasing evidence that asymptomatic spinal cord lesions can occur, independently of brain disease activity. Despite these cord lesions being asymptomatic, they impact disability accrual in the long term. Although this might be an imaging marker for monitoring and treatment, it is not yet applied in the clinical setting. The investigators will prospectively collect spinal cord MRI data (in addition to routine brain MRI), and blood-based biomarkers (plus cerebral spinal fluid markers, if available), in recently diagnosed MS patients, to address the following research questions: * What is the incidence of asymptomatic spinal cord lesions in patients commencing DMT? * And in the absence of radiological progression on brain imaging, how frequently do asymptomatic spinal cord lesions occur? In other words, how often is disease activity solely proven by spinal cord MRI and what is the number-needed-to-scan? * A secondary o…
This description comes directly from the study's public registry record.
Demmie Bouweriks, MD · +31884597603 · d.bouweriks@zuyderland.nl
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients between 18 and 65 years old * Patients diagnosed with relapsing-remitting MS (≤5 years of first clinical event) * Treatment-naïve patients starting (currently in the Netherlands approved) DMT Exclusion Criteria: * Patients who presented first clinical event more than five years ago * Patients who have already started DMT * Patients who are incapable of giving informed consent * Patients who are unable to undergo local MRI scan, due to for instance * Physical problems, for instance due to size/obesity (not fitting in regular MRI scanner), not being able to lie flat for extended periods of time (e.g. due to pain, shortness of breath) * Due to claustrophobia * Patients who have contraindications for MRI scan, for instance * Due to MRI-unsafe or non-compatible implanted material/devices, such as pacemakers or ocular metal splinters * Patients who are pregnant at inclusion
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Rijnstate | Arnhem, Gelderland, Netherlands | Not Yet Recruiting |
| Zuyderland Medisch Centrum | Geleen, Limburg, Netherlands | Recruiting |
| Jeroen Bosch Ziekenhuis | 's-Hertogenbosch, North Brabant, Netherlands | Not Yet Recruiting |
| Albert Schweitzer ziekenhuis | Dordrecht, South Holland, Netherlands | Recruiting |
| Erasmus MC | Rotterdam, South Holland, Netherlands | Not Yet Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06827834